AACR 2012: ABT-199 shows promise in CLL

At the 2012 annual meeting of the American Association for Cancer Research (AACR), Steven W. Elmore from Abbott Laboratories presented impressive initial data on ABT-199, a potent and selective inhibitor of Bcl-2, currently in a phase I clinical trial for Chronic Lymphocytic Leukemia (CLL).

4,063 total views
  1. Pieter Droppert writes the Biotech Strategy Blog and this Storify is part of a series of posts about the 2012 annual meeting of the American Association for Cancer Research (AACR).
Like
Share

Share

Facebook
Google+